Introduction to Pharmacodynamics

Course Learning Outcomes

After successful completion of this course, the student will be able to:

1. Identify the fundamentals of cell biology and genetics that impact physiological and pathophysiological function.

2. Recognize the alterations that occur in diseases at the molecular, cellular, and tissue level.

3. Identify the molecular and cellular mechanisms by which signals are transmitted into physiological responses.

4. Identify the molecular and cellular mechanisms by which drugs elicit their therapeutic effects.

5. Recognize fundamental physiologic, pathophysiologic, and pharmacologic concepts and their application to understanding the integrative nature of organ system function in maintaining homeostasis in health.

USC COP Educational Outcomes

1.1. Foundational knowledge

Lecture Learning Outcomes

By the end of this lecture, students should be able to:

1. Define pharmacodynamics (PD) and distinguish it from pharmacokinetics (PK).

2. Describe Receptor Occupancy Theory – how receptor binding (occupancy) translates into pharmacologic effect.

3. Evaluate dose-response curves to determine key drug properties (graded vs. quantal, Kd, EC₅₀, Emax, potency, efficacy, ED₅₀, LD₅₀).

4. Differentiate classes of drugs based on their mechanisms of action (orthosteric vs. allosteric, agonist vs. antagonist, reversible vs. irreversible) with representative examples.

5. Explain tolerance and tachyphylaxis, and why drug effects may decline over time.

6. Define therapeutic index (TI) and discuss its role in drug safety and selectivity.

7. Apply these concepts to real-life drug examples.

Pharmacology: The Study of Chemical Actions on Biological Systems

Medical pharmacology is the area of pharmacology concerned with the use of chemicals in the prevention, diagnosis, and treatment of disease.

• Toxicology is the area of pharmacology concerned with the undesirable effects of chemicals on biologic systems.

• Pharmacokinetics (PK) describes the effects of the body on drugs:

  • Absorption

  • Distribution

  • Metabolism

  • Excretion (ADME)

• Pharmacodynamics (PD) denotes the actions of the drug on the body:

  • Mechanism of action

  • Therapeutic effects and toxic effects

Pharmacodynamics vs. Pharmacokinetics

• PK: What the body does to the drug, often described as drug concentration influencing the pharmacologic effect.

• PD: What the drug does to the body, emphasizing how drug effects and actions manifest in physiological changes.

Pharmacodynamics: What the Drug Does to the Body

DEFINITION: The study of the biochemical and physiological effects of drugs and their mechanisms of action.

Receptor Occupancy Theory

• Receptors are specific molecules in a biologic system that interact with drugs to produce changes in systemic functions.

• Receptor binding (occupancy) translates into pharmacologic effect; understanding this process is critical for pharmacological interventions.

Receptors: Where Drugs Bind and Act

• In the context of Occupancy Theory, a “Receptor” is any binding site for a drug on a biological macromolecule. This could include:

  • Enzymes

  • Ion channels

  • Transporters

  • Structural proteins

  • DNA

• Modern pharmacology uses “drug targets” as a broader, more precise term, where receptors are specific subclasses of drug targets specifically involving proteins that bind ligands and transduce signals. Examples include:

  • Ligand-gated ion channels: GABAA receptor, nACh receptor.

  • Receptor types: µ-opioid receptor, H1 receptor, β2 adrenergic receptors.

  • Nuclear receptors: AR (androgen receptor), ER (estrogen receptor), RAR (retinoic acid receptor).

  • Receptor Tyrosine Kinases: EGFR (epidermal growth factor receptor), Insulin Receptor (InsR), FGFR (fibroblast growth factor receptor).

Effectors: Where Response Happens

• Effectors refer to molecules that translate the drug-receptor interaction into changes in cellular activity.

  • Receptor = “signal detector”

  • Effector = “response generator”

• Together, they form the signal transduction pathway which links drug binding to physiological effects.

Example:

• Albuterol (the drug) binds to the β2-adrenergic receptor (the receptor) → activates adenylyl cyclase (the effector) → increases cAMP (second messenger) → activates PKA (effector) → downstream effectors targeting physiological changes (smooth muscle relaxation results in bronchodilation).

• Mechanism: PKA activation decreases Ca²⁺ influx and inhibits MLCK (myosin light chain kinase).

Drug Classification by Mechanism of Action

1. By Binding Site:

   • Orthosteric: Binds at the natural ligand site (e.g., albuterol at β2 receptor).

   • Allosteric: Binds at a different site, modulating receptor function (e.g., benzodiazepines at GABA_A receptor).

2. By Functional Effect:

   • Agonist: Activates receptor and produces effects (e.g., full vs. partial agonists).

   • Antagonist: Binds but does not activate, blocks agonist activity (e.g., competitive vs. non-competitive).

3. By Mode of Modulation:

   • Activator: Increases activity of the target (e.g., allosteric activators, channel openers).

   • Inhibitor: Decreases activity of the target (e.g., enzyme inhibitors, channel blockers).

4. By Chemical Interaction:

   • Non-covalent (reversible): Involves hydrogen bonds, ionic bonds, and hydrophobic forces (most drugs).

   • Covalent (irreversible): Involves permanent bonding resulting in long duration effects (e.g., aspirin with COX).

Agonist and Antagonist

• Agonist:

  • Binds to the active (orthosteric) site and activates the receptor.

  • Examples: β2-receptor agonist albuterol for asthma.

• Antagonist:

  • Binds to the receptor but blocks agonist-mediated receptor activation.

  • Examples: β1-receptor blocker metoprolol for cardiovascular conditions.

• Endogenous ligands are natural agonists, e.g., epinephrine, estradiol, testosterone.

Allosteric Drugs: Acting Away from the Active Site

• Positive Allosteric Modulator (PAM):

  • Example: Alprazolam

  • Target: GABA-A receptor

  • Action: Binds to allosteric site, enhances effect of GABA leading to increased chloride influx and neuronal inhibition

  • Used for: Anxiety, epilepsy, insomnia

• Negative Allosteric Modulator (NAM):

  • Example: Efavirenz

  • Target: HIV-1 reverse transcriptase

  • Action: Binds allosterically, changes enzyme conformation, inhibits viral DNA synthesis

  • Used for: HIV/AIDS

Dose–Response Curves: The Foundation of Pharmacodynamics

• Dose–response curves illustrate the relationship linking drug dose to its effects.

• They show that effects depend on drug dose/concentration, helping to understand drug action, safety, and clinical use.

Importance of Dose-Response Curves

1. Predict drug effects at varying doses.

2. Compare drugs for potency and safety.

3. Form the basis for understanding agonists, antagonists, and modulators.

4. Inform clinical dosing regimens.

Two Types of Dose-Response Curves: Graded vs. Quantal

Features:

Definitions:

• Quantal Dose–Response Curve:

  • Measures all-or-none responses in a population.

  • X-axis: Drug dose

  • Y-axis: % of individuals showing a defined effect

• Graded Dose-Response Curve:

  • Measures continuous response in a single subject/system.

  • X-axis: Drug dose (usually on log scale)

  • Y-axis: Magnitude of response (e.g., % maximal effect)

Graded Dose–Response Curves

• They display a continuous, measurable response in a single subject.

• Example: Heart rate changes with increasing drug dose.

Parameters:

• Emax: Maximum effect

• EC₅₀: Effective concentration at 50% of Emax

Curve Characteristics:

• Usually sigmoidal (log-dose vs. response)

• Used for assessing drug potency and efficacy.

Drug–Receptor Interactions (Binding Affinities)

• Thermodynamics Equation:
  $<br>\Delta G = \Delta H - T \Delta S <br>$

• If \Delta G < 0, the reaction is spontaneous.

• If $\Delta G = 0$, the system is at equilibrium.

Standard Conditions Equation Version:

• $\Delta G = \Delta G^\circ + RT \ln(Q)$

  • Where:

    • $\Delta G^\circ$ = Standard Gibbs free energy change (at 1 atm, 298K, 1 M)

    • $R$ = Gas constant (8.314 J/mol·K or 1.987 cal/mol·K)

    • $T$ = Temperature in Kelvin

    • $Q$ = Reaction quotient (ratio of products to reactants)

• At equilibrium ($\Delta G = 0$, and $Q = K$):
  $\Delta G^\circ = -RT \ln(K)$

• The binding affinity is directly related to the standard Gibbs free energy change:
  $\Delta G^\circ = -RT \ln(K<em>a)$ or equivalently (using Kd, the dissociation constant): $\Delta G^\circ = RT \ln(K</em>d)$

• Where: $K<em>a = \text{association constant (1/Kd)}$ (higher $K</em>a$ = stronger binding)

• $K<em>d =$ dissociation constant, in M (lower $K</em>d$ = stronger binding)

Receptor Occupancy Theory: Deeper Dive into the Math

• The binding ratio can be expressed as $\frac{(1-y)}{y}$.

• The equilibrium expression will be based on receptor-ligand binding.

Assumptions:

• Assume receptor concentration is much smaller than drug concentration.

• Let:

  • Let $x = D$ (free drug concentration)

  • Let $y$ = fraction (or % if ×100) of receptors bound

Graded Dose–Response Curve

• Increasing drug dose (concentration) → greater % receptor occupancy → greater effect.

• In assays, a graded dose-response curve is obtained by measuring how the response of a receptor-effector system varies with increasing drug concentrations or doses.

Kd versus EC₅₀: Example 1

• KD and EC50 are similar in the textbook ‘ideal’ case where drug effects are directly proportional to receptor occupancy.

Kd versus EC₅₀: Example 2

• Spare receptors: Exist in excess of what is needed for maximal response, meaning not all receptors need to be occupied to achieve Emax (maximum effect).

• Example: Insulin receptors have a significant “spare” receptor population ensuring strong glucose uptake at low hormone concentrations.

• In this context, KD is typically higher than EC50.

Drugs: Efficacy versus Potency

• Efficacy (Maximal Efficacy): The greatest effect (Emax) a drug can produce.

• Potency: Refers to the amount of drug needed to achieve a specified effect.

• The drug with the lower EC50 or Kd is deemed more potent, whereas the drug eliciting the greater effect is considered more efficacious.

Quantal Dose–Response Curve

• The median effective dose (ED50), median toxic dose (TD50), and in animals median lethal dose (LD50) are derived from experiments conducted to measure all-or-none responses in a population.

Definition:

• Quantal Dose–Response Curve: Measures binary responses in a population.

• X-axis: Drug dose

• Y-axis: % of individuals showing a defined effect.

Summary (Part I)

1. Pharmacodynamics (PD) vs. Pharmacokinetics (PK):

   • PD: What the drug does to the body

   • PK: What the body does to the drug (ADME)

2. Different Classes of Drugs:

   • Orthosteric vs. Allosteric

   • Agonists vs. Antagonists

3. Receptor Occupancy Theory:

   • Drugs bind to receptors to initiate effects

   • Binding characterized by affinity (Kd)

4. Dose–Response Curves:

   • Graded response: % effect vs. drug concentration

   • Key terms: Kd, EC₅₀, Emax, potency, efficacy

   • Quantal response: population-based, showing ED₅₀, LD₅₀

Different Types of Agonists

• Agonist: Any molecule that binds to a receptor and produces a biological response.

• Endogenous ligands: Include neurotransmitters, hormones, and growth factors that act as natural agonists (e.g., acetylcholine for nicotinic receptors, dopamine for dopamine receptors, epinephrine/norepinephrine for adrenergic receptors).

• Types:

  • Full agonist: Binds and produces maximum possible response (Emax).

  • Partial agonist: Binds and activates receptor but produces submaximal response even when all receptors are occupied.

  • Inverse agonist: Binds to the same site as an agonist and produces an opposite effect, reducing basal constitutive activity (active without agonist).

Different Types of Agonists - Summary Table

Full Agonists Differing in Potency

• Full agonists reach the same maximal effect (Emax) but may differ in potency.

• Example: Nicotine shows a leftward shift in the curve, indicating higher potency.

Agonists Differing in Efficacy

• Morphine: Full agonist reaching Emax = 1.0.

• Buprenorphine: High potency (left-shifted EC₅₀) but exhibits partial efficacy.

Different Types of Antagonists

• An antagonist is a drug or molecule that binds to a receptor but does not interfere with its basal activity (has affinity but no efficacy), thereby blocking or reducing the effects of an agonist.

Antagonist Types:

1. Competitive Antagonists:

   • Binds reversibly to the same active site as the agonist.

   • Competes with the agonist for binding; effects can be overcome by increasing agonist concentration.

   • Influences the dose-response curve by shifting it to the right (↑EC₅₀) without changing Emax.

2. Non-competitive Antagonists:

   • Binds to a different (allosteric) site or irreversibly to the active site.

   • Reduces receptor availability regardless of agonist concentration and decreases Emax while EC50 can remain unchanged or slightly adjusted.

Competitive vs. Non-competitive Antagonists

• Competitive Antagonists: Shift the agonist curve to the right.

• Non-competitive Antagonists: Shift the agonist curve downwards.

Graphical Presentation

• Graphs represent how competitive antagonism decreases potency and non-competitive antagonism decreases efficacy, illustrating these shifts and their implications on drug response curves.

Types of Antagonists - Additional Categories

3. Physiological Antagonists:

   • Bind to a different receptor, producing effects opposite those of the drug they antagonize.

   • Examples:

     • Antagonism of bronchoconstriction caused by histamine through epinephrine's bronchodilator action.

     • Glucagon's antagonism of insulin’s hypoglycemic effects.

4. Chemical Antagonists:

   • Interact directly with the drug being antagonized to remove or prevent it from binding to its target.

   • Examples:

     • Dimercaprol, which chelates lead and some other toxic metals.

5. Functional Antagonists:

   • Effects by partial agonists and inverse agonists, thereby reducing a full agonist's effect while occupying the receptor, preventing a full response.

   • Key differences from competitive antagonists include reducing the agonist’s efficacy while having its own intrinsic efficacy.

Partial Agonist Activity Explained: Case of Varenicline

• Varenicline (Chantix): Functions as both a partial agonist and antagonist.

  • Activity: Binds to nicotinic acetylcholine receptors, producing mild to moderate activation. This partial stimulation releases low levels of dopamine, helping reduce nicotine withdrawal symptoms and cravings.

  • Antagonist activity: If a person smokes, Varenicline’s high affinity for the receptor outcompetes nicotine for the binding site, blocking the powerful dopamine release associated with smoking reward effects.

Tolerance vs. Tachyphylaxis

Features:

Examples:

• Tolerance:

  • A gradual decrease in drug effect after chronic exposure, developing slowly due to receptor downregulation, increased metabolism, or compensatory adaptations (e.g., opioid analgesics).

• Tachyphylaxis:

  • Rapid decrease in drug effect following short-term dosing, developing quickly due to receptor desensitization, mediator depletion (e.g., nasal decongestants like oxymetazoline).

Drug Selectivity

• Definition: How selectively a drug binds to and acts on its intended receptor.

• Key Concepts:

  • Selectivity refers to preferential activation or inhibition of the desired target.

  • High selectivity is characterized by low/no affinity for other receptors, thus decreasing potential off-target toxicity.

  • The degree of selectivity can be quantified by calculating the ratio of Kd or EC50 values for different interactions.

  • Drug selectivity is crucial for successful drug development.

Drug-Target Selectivity

Considerations:

• Between species:

  • Prioritize unique targets in invading pathogens, ensuring targeting is not harmful to host.

• Within the body:

  • Focus on selectivity among different enzymes and receptors.

  • Emphasize distinction among receptor types and subtypes, and between isozymes.

Improving Drug Selectivity

• An essential step in drug discovery which may involve hit-to-lead optimization to refine the selectivity of compounds based on their activity in target cells versus cells with the target knocked out.

Therapeutic Index (TI)

Definition:

• A measure of a drug’s safety margin, defined as the ratio between doses that cause toxic effects and those that produce therapeutic effects.

• Formula: $TI = \frac{TD<em>{50}}{ED</em>{50}}$

  • Where:

  • ED₅₀: Dose effective in 50% of subjects

  • TD₅₀ / LD₅₀: Dose toxic (or lethal) in 50% of subjects

Interpretation:

1. A high TI indicates a safer drug (large margin between effective and toxic doses).

2. A low TI indicates a narrow safety margin, requiring careful monitoring.

Examples:

• Wide TI: Penicillin, Benzodiazepines

• Narrow TI: Digoxin, Warfarin

Assessing Therapeutic Index

• Recommendations state to maximize the TI; an approximate value greater than 10 is considered high.

Comparing Therapies

Quantal Dose-Response Curves

• Demonstrates slopes affecting variability in population responses to drugs.

Implications:

• Low slope: Signifies greater variability and reflects diverse pharmacokinetics and/or dynamics.

• High slope: Indicates more uniform drug sensitivity among the population.

Advantages/Disadvantages:

• Advantages:

  • Predictable dosing

  • Beneficial for critical or fast-acting therapies (e.g., anesthetics).

• Disadvantages:

  • Narrow safety margins if toxicity has a steep slope.

  • Low tolerance for dosing errors or patient variability.

Reviewing Learning Objectives

By the end of this lecture, students should be able to:

1. Define pharmacodynamics (PD) and distinguish it from pharmacokinetics (PK).

2. Describe Receptor Occupancy Theory – how receptor binding (occupancy) translates into pharmacologic effect.

3. Evaluate dose-response curves to determine key drug properties (graded vs. quantal, Kd, EC₅₀, Emax, potency, efficacy, ED₅₀, LD₅₀).

4. Differentiate classes of drugs based on their mechanisms of action (orthosteric vs. allosteric, agonist vs. antagonist, reversible vs. irreversible) with representative examples.

5. Explain tolerance and tachyphylaxis, and why drug effects may decline over time.

6. Define therapeutic index (TI) and discuss its role in drug safety and selectivity.

7. Apply these concepts to real-life drug examples.

Introduction to Pharmacodynamics

Dr. Mengqian (Max) Chen

College of Pharmacy, University of South Carolina

chenm@cop.sc.edu

09/29/2025 & 10/03/2025

PHMY602-FALL-2025 Foundations of Pathophysiology and Pharmacology I

Course Learning Outcomes

After successful completion of this course, the student will be able to:

1. Identify the fundamentals of cell biology and genetics that impact physiological and pathophysiological function.

2. Recognize the alterations that occur in diseases at the molecular, cellular, and tissue level.

3. Identify the molecular and cellular mechanisms by which signals are transmitted into physiological responses.

4. Identify the molecular and cellular mechanisms by which drugs elicit their therapeutic effects.

5. Recognize fundamental physiologic, pathophysiologic, and pharmacologic concepts and their application to understanding the integrative nature of organ system function in maintaining homeostasis in health.

USC COP Educational Outcomes

1.1. Foundational knowledge

Lecture Learning Outcomes

By the end of this lecture, students should be able to:

1. Define pharmacodynamics (PD) and distinguish it from pharmacokinetics (PK).

2. Describe Receptor Occupancy Theory – how receptor binding (occupancy) translates into pharmacologic effect.

3. Evaluate dose-response curves to determine key drug properties (graded vs. quantal, $K<em>d$, $EC</em>{50}$, $E<em>{max}$, potency, efficacy, $ED</em>{50}$, $LD_{50}$).

4. Differentiate classes of drugs based on their mechanisms of action (orthosteric vs. allosteric, agonist vs. antagonist, reversible vs. irreversible) with representative examples.

5. Explain tolerance and tachyphylaxis, and why drug effects may decline over time.

6. Define therapeutic index (TI) and discuss its role in drug safety and selectivity.

7. Apply these concepts to real-life drug examples.

Pharmacology: The Study of Chemical Actions on Biological Systems

Medical pharmacology is the area of pharmacology concerned with the use of chemicals in the prevention, diagnosis, and treatment of disease. It investigates how drugs interact with biological systems to produce desired therapeutic outcomes.

• Toxicology is the area of pharmacology concerned with the undesirable effects of chemicals on biologic systems, including adverse drug reactions, poisoning, and environmental toxins.

• Pharmacokinetics (PK) describes the effects of the body on drugs, governing how drug concentrations change over time within the body. This process is summarized by:

  • Absorption: The movement of a drug from its site of administration into the systemic circulation.

  • Distribution: The reversible transfer of a drug from one site to another within the body.

  • Metabolism: The chemical conversion of drugs into metabolites, primarily by enzymes, often in the liver.

  • Excretion: The irreversible removal of drugs or their metabolites from the body, typically via kidneys or liver.

  (These four processes are collectively known as ADME).

• Pharmacodynamics (PD) denotes the actions of the drug on the body, involving the biochemical and physiological effects, as well as their mechanisms of action.

  • Mechanism of action: How the drug interacts with molecular targets to produce its effects.

  • Therapeutic effects and toxic effects: The beneficial and harmful physiological outcomes of drug action.

Pharmacodynamics vs. Pharmacokinetics

• PK: What the body does to the drug. This includes how the drug is absorbed, distributed, metabolized, and excreted, ultimately influencing the drug's concentration at its site of action and, therefore, its pharmacologic effect.

• PD: What the drug does to the body. This emphasizes how drug effects and actions manifest in physiological changes, defining the therapeutic and potential toxic responses.

Pharmacodynamics: What the Drug Does to the Body

DEFINITION: The study of the biochemical and physiological effects of drugs and their mechanisms of action. It explores the relationship between drug concentration at the site of action and the resulting effect.

Receptor Occupancy Theory

• Receptors are specific macromolecules, typically proteins, in a biologic system that interact with drugs to mediate their effects. This interaction usually involves reversible binding.

• Receptor binding (occupancy) translates into a pharmacologic effect; understanding this process is critical for pharmacological interventions, as the magnitude of the effect is generally proportional to the number of receptors occupied.

Receptors: Where Drugs Bind and Act

• In the context of Occupancy Theory, a “Receptor” is broadly defined as any binding site for a drug on a biological macromolecule that can initiate a cellular response. This could include:

  • Enzymes: Proteins that catalyze biochemical reactions (e.g., COX-1/2 for NSAIDs).

  • Ion channels: Membrane proteins that regulate ion flow across cell membranes (e.g., voltage-gated sodium channels for local anesthetics).

  • Transporters: Proteins that move molecules across membranes (e.g., SERT for SSRIs).

  • Structural proteins: Proteins integral to cell structure (e.g., tubulin for anti-cancer drugs).

  • DNA: Genetic material that can be targeted by certain drugs (e.g., chemotherapy agents).

• Modern pharmacology uses “drug targets” as a broader, more precise term, encompassing all macromolecules a drug interacts with. Receptors, in a stricter sense, are specific subclasses of drug targets specifically involving proteins that bind endogenous ligands and transduce extracellular signals into intracellular responses. Examples include:

  • Ligand-gated ion channels (ionotropic receptors): Fast-acting receptors that open or close an ion channel upon ligand binding (e.g., GABA$_A$ receptor, nicotinic acetylcholine (nACh) receptor). They mediate synaptic transmission.

  • G protein-coupled receptors (GPCRs or metabotropic receptors): The largest family of membrane receptors that indirectly activate intracellular signaling cascades via G proteins (e.g., $\mu$-opioid receptor, H1 receptor, ${\beta}_2$ adrenergic receptors). They mediate slower, more prolonged responses.

  • Nuclear receptors: Intracellular receptors that, when activated by lipid-soluble ligands (like steroid hormones), translocate to the nucleus to regulate gene expression (e.g., AR (androgen receptor), ER (estrogen receptor), RAR (retinoic acid receptor)).

  • Receptor Tyrosine Kinases (RTKs): Membrane receptors that, upon ligand binding, dimerize and phosphorylate tyrosine residues on themselves and other proteins, initiating signaling cascades involved in cell growth and differentiation (e.g., EGFR (epidermal growth factor receptor), Insulin Receptor (InsR), FGFR (fibroblast growth factor receptor)).

Effectors: Where Response Happens

• Effectors refer to molecules (often enzymes, ion channels, or other proteins) that translate the drug-receptor interaction into a measurable change in cellular activity or physiological response. They are often part of a signal transduction pathway.

  • Receptor = “signal detector” (receives the initial signal from the drug/ligand).

  • Effector = “response generator” (produces the biochemical or physiological change).

• Together, they form the signal transduction pathway which links drug binding to a series of intracellular events that culminate in physiological effects.

Example:

• Albuterol (the drug, a ${\beta}<em>2$ adrenergic agonist) binds to the ${\beta}</em>2$-adrenergic receptor (the receptor) on bronchial smooth muscle cells, causing a conformational change. This activated receptor interacts with a G-protein, leading to the activation of adenylyl cyclase (the primary effector enzyme). Adenylyl cyclase then catalyzes the conversion of ATP to cAMP (second messenger), which in turn activates protein kinase A (PKA) (another effector). PKA then phosphorylates various downstream effectors, specifically targeting proteins involved in calcium regulation and smooth muscle contraction/relaxation. These physiological changes ultimately result in smooth muscle relaxation and bronchodilation (e.g., in asthma).

• Mechanism detailed: PKA activation decreases intracellular $Ca^{2+}$ influx by inhibiting voltage-gated calcium channels and enhances calcium sequestration, leading to reduced free intracellular $Ca^{2+}$. Additionally, PKA inhibits MLCK (myosin light chain kinase), which is essential for smooth muscle contraction. By inhibiting MLCK, PKA prevents the phosphorylation of myosin light chains, thus promoting relaxation.

Drug Classification by Mechanism of Action

Drugs can be categorized based on how they interact with their targets and produce their effects:

1. By Binding Site:

   • Orthosteric: These drugs bind precisely at the primary, natural ligand binding site (also known as the active site) on the receptor. This is where the endogenous ligand typically binds (e.g., albuterol binding at the ${\beta}_2$ receptor's ligand-binding site).

   • Allosteric: These drugs bind at a distinct site on the receptor, separate from the orthosteric site. Their binding causes a conformational change that modulates the receptor's affinity for the orthosteric ligand or its signaling efficiency (e.g., benzodiazepines binding at an allosteric site on the $GABA_A$ receptor to enhance GABA's effect).

2. By Functional Effect:

   • Agonist: A drug that binds to a receptor and activates it, mimicking the effect of the endogenous ligand and producing a biological response. Agonists possess both affinity (ability to bind) and intrinsic activity (ability to activate the receptor and produce an effect). They can be full agonists (producing maximal response) or partial agonists (producing submaximal response).

   • Antagonist: A drug that binds to a receptor but does not activate it (has affinity but no intrinsic activity). Instead, antagonists block the binding of agonists (either endogenous or exogenous) and thus prevent their receptor activation and subsequent effects (e.g., metoprolol blocking ${\beta}_1$ adrenergic receptors).

3. By Mode of Modulation:

   • Activator: A molecule that directly or indirectly increases the activity of its target (e.g., allosteric activators that enhance enzyme activity or channel openers that facilitate ion flow).

   • Inhibitor: A molecule that decreases or stops the activity of its target (e.g., enzyme inhibitors that block substrate binding, or channel blockers that prevent ion passage).

4. By Chemical Interaction:

   • Non-covalent (reversible): Most drugs form reversible bonds with their receptors, involving weaker intermolecular forces such as hydrogen bonds, ionic bonds, van der Waals forces, and hydrophobic interactions. These interactions are transient, allowing the drug to bind and dissociate, explaining the finite duration of many drug effects.

   • Covalent (irreversible): Some drugs form stable, permanent covalent bonds with their receptors. This leads to long-lasting effects because the drug-receptor complex is very stable, and the receptor function is often restored only after new receptor synthesis (e.g., aspirin irreversibly inhibiting COX enzymes).

Agonist and Antagonist

• Agonist: A substance that possesses both affinity for a receptor and intrinsic activity, meaning it binds to the active (orthosteric) site and activates the receptor to produce a biological response.

  • Examples: ${\beta}_2$-receptor agonist albuterol is used for asthma to induce bronchodilation.

• Antagonist: A substance that has affinity for a receptor but lacks intrinsic activity. It binds to the receptor but blocks agonist-mediated receptor activation, preventing the normal biological response.

  • Examples: ${\beta}_1$-receptor blocker metoprolol is used for cardiovascular conditions like hypertension and angina to reduce heart rate and contractility.

• Endogenous ligands are natural agonists produced by the body, such as neurotransmitters, hormones, or growth factors (e.g., epinephrine and norepinephrine for adrenergic receptors, estradiol for estrogen receptors, testosterone for androgen receptors).

Allosteric Drugs: Acting Away from the Active Site

Allosteric modulators bind to a site on the receptor distinct from the orthosteric (agonist) binding site and can either enhance or diminish the effect of an orthosteric agonist without being agonists or antagonists themselves.

• Positive Allosteric Modulator (PAM): A drug that binds to an allosteric site and increases the effect of the primary (orthosteric) ligand. PAMs enhance the affinity of the primary ligand for the receptor, or increase the efficiency of receptor activation once the orthosteric ligand is bound.

  • Example: Alprazolam (a benzodiazepine)

  • Target: $GABA_A$ receptor (an ion channel in the central nervous system).

  • Action: Alprazolam binds to a specific allosteric site on the $GABA_A$ receptor. While it does not directly activate the channel, its binding enhances the effect of the inhibitory neurotransmitter GABA, leading to increased frequency of chloride channel opening. This increased chloride influx hyperpolarizes the neuron, resulting in neuronal inhibition.

  • Used for: Treating anxiety, epilepsy, and insomnia by enhancing central nervous system depression.

• Negative Allosteric Modulator (NAM): A drug that binds to an allosteric site and decreases the effect of the primary (orthosteric) ligand. NAMs can reduce the affinity of the primary ligand or decrease the efficacy of receptor activation.

  • Example: Efavirenz

  • Target: HIV-1 reverse transcriptase (an enzyme crucial for viral replication).

  • Action: Efavirenz binds allosterically to a non-active site on the HIV-1 reverse transcriptase. This binding induces a conformational change in the enzyme, which inhibits its catalytic activity, thereby preventing the synthesis of viral DNA from RNA.

  • Used for: As an antiretroviral medication in the treatment of HIV/AIDS.

Dose–Response Curves: The Foundation of Pharmacodynamics

• Dose–response curves are fundamental graphical representations that illustrate the relationship linking the drug dose or concentration to the magnitude of its observed biological effect. They are typically plotted with drug concentration (often on a logarithmic scale) on the x-axis and the observed effect on the y-axis.

• These curves are essential for quantifying drug action, understanding its efficacy and potency, characterizing its safety profile, and guiding optimal clinical application.

Importance of Dose-Response Curves

1. Predict drug effects at varying doses: Allows clinicians and researchers to anticipate the level of response at different drug exposures.

2. Compare drugs for potency and efficacy: Provides a quantitative method to compare the relative strength and maximal effect of different pharmacological agents.

3. Form the basis for understanding agonists, antagonists, and modulators: Different drug classes produce characteristic shifts or changes in dose-response curves, which help to define their mechanisms.

4. Inform clinical dosing regimens: Critical for establishing appropriate and safe starting doses, titration schedules, and therapeutic ranges for drugs in patients.

Two Types of Dose-Response Curves: Graded vs. Quantal

Features:

Definitions:

• Quantal Dose–Response Curve:

  • Measures the frequency of an all-or-none (binary) response within a large population of individuals.

  • X-axis: Drug dose (or concentration), typically on a logarithmic scale.

  • Y-axis: The cumulative percentage of individuals in the population showing a defined effect (e.g., 50% of patients experiencing pain relief, 10% showing toxicity).

• Graded Dose-Response Curve:

  • Measures a continuous, quantifiable response in a single biological system (e.g., an isolated tissue, cell culture, or a single patient).

  • X-axis: Drug dose or concentration, usually on a logarithmic scale to span a wide range of concentrations and often linearize the mid-portion of the curve.

  • Y-axis: Magnitude of response, expressed as a percentage of the maximal achievable effect (e.g., % maximal enzyme inhibition, % maximal muscle contraction).

Graded Dose–Response Curves

These curves plot the magnitude of a biological response against increasing drug concentration or dose in a single biological unit or patient. They display a continuous, measurable response, illustrating how the intensity of the effect increases with dose until a maximum is reached.

• Example: The increase in heart rate (a continuous variable) observed with increasing doses of a ${\beta}_1$ adrenergic agonist in a single individual.

Parameters:

• $\textbf{E}_{max}$: Maximum effect or maximal efficacy; the plateau of the dose-response curve, representing the greatest possible response that can be produced by the drug, even with further increases in dose. This reflects the drug's intrinsic activity and the capacity of the biological system.

• $\textbf{EC}<em>{50}$: Effective concentration at 50% of $\textbf{E}</em>{max}$; the drug concentration (or dose) that produces 50% of the maximum possible effect. $EC<em>{50}$ is a key measure of a drug's potency: a lower $EC</em>{50}$ indicates a more potent drug.

Curve Characteristics:

• Typically, graded dose-response curves are sigmoidal when plotted against the logarithm of the drug concentration vs. response. This shape implies that responses are small at low concentrations, increase steeply over a critical range of concentrations, and then plateau at high concentrations.

• They are primarily used for assessing drug potency (how much drug is needed for an effect) and efficacy (the maximal effect a drug can produce).

Drug–Receptor Interactions (Binding Affinities)

The interaction between a drug and its receptor is governed by chemical forces and thermodynamic principles. The strength of this interaction is known as binding affinity.

• Thermodynamics Equation for Gibbs Free Energy:

  $\Delta G = \Delta H - T \Delta S$

  Where: $\Delta G$ is the change in Gibbs free energy, $\Delta H$ is the change in enthalpy (heat), $T$ is the temperature in Kelvin, and $\Delta S$ is the change in entropy (disorder).

• If \Delta G < 0, the reaction (drug-receptor binding) is thermodynamically spontaneous and favored.

• If $\Delta G = 0$, the system is at equilibrium, meaning the rates of association and dissociation are equal.

Standard Conditions Equation Version:

• The change in Gibbs free energy under non-standard conditions is given by:

  $\Delta G = \Delta G^\circ + RT \ln(Q)$

  • Where:

    • $\Delta G^\circ$ = Standard Gibbs free energy change (at 1 atm pressure, 298K temperature, and 1 M concentration for all reactants and products in ideal solutions).

    • $R$ = Gas constant (8.314 J/mol·K or 1.987 cal/mol·K).

    • $T$ = Temperature in Kelvin.

    • $Q$ = Reaction quotient, which describes the relative amounts of products and reactants present in a reaction at any given time.

  • At equilibrium ($\Delta G = 0$, and the reaction quotient $Q$ becomes the equilibrium constant $K$):

    $\Delta G^\circ = -RT \ln(K)$

  • For drug-receptor binding, the binding affinity itself is directly related to the standard Gibbs free energy change:

    $\Delta G^\circ = -RT \ln(K<em>a)$ or equivalently (using $K</em>d$, the dissociation constant): $\Delta G^\circ = RT \ln(K_d)$

  • Where: $K<em>a$ = association constant ($1/K</em>d$) (A higher $K_a$ value indicates stronger binding affinity; the drug associates more readily with the receptor).

  • $\textbf{K}<em>d$ = dissociation constant, typically expressed in molarity (M). A lower $K</em>d$ value indicates stronger binding affinity because less drug is needed to occupy half of the receptors; it means the drug dissociates less readily from the receptor.

Receptor Occupancy Theory: Deeper Dive into the Math

This theory postulates that the magnitude of a drug's effect is directly proportional to the fraction of receptors occupied by the drug. For a simple reversible binding equilibrium, the relationship between drug concentration and receptor occupancy can be described by the following equations, derived from the law of mass action:

• The binding ratio, or fraction of receptors unbound to bound ($\frac{\text{[R]}}{\text{[DR]}}$ where [R] is free receptor and [DR] is drug-receptor complex), can be expressed using the fraction of occupied receptors ($y$) as $\frac{(1-y)}{y}$.

• The equilibrium expression for drug-receptor binding ($D + R \rightleftharpoons DR$) is based on the dissociation constant ($K_d$) which is $\frac{[D][R]}{[DR]}$.

Assumptions:

• Assume the total receptor concentration (receptor sites available) is much smaller than the drug concentration (ligand in solution) at therapeutically relevant doses; thus, drug concentration remains relatively constant upon binding.

• Let:

  • Let $x = [D]$ (free drug concentration at the receptor site).

  • Let $y$ = fraction (or % if ×100) of total receptors bound by the drug ($\frac{[DR]}{[R]_{\text{total}}}$).

This leads to the simplified relationship known as the Hill-Langmuir equation for receptor occupancy: $y = \frac{[D]}{[D] + K<em>d}$. This equation shows that when $[D] = K</em>d$, half of the receptors are occupied ($y = 0.5$).

Graded Dose–Response Curve: Linking Occupancy to Effect

• In an ideal scenario, increasing drug dose (concentration) directly leads to a greater percentage of receptor occupancy, which in turn results in a greater pharmacologic effect, until all receptors are occupied or maximum physiological response is achieved.

• In assays, a graded dose-response curve is obtained by measuring how the continuous response of a receptor-effector system varies with increasing drug concentrations or doses, providing insights into the drug's potency and efficacy. The initial part of the curve reflects increasing occupancy, and the plateau reflects maximum occupancy or maximal intrinsic activity.

$K<em>d$ versus $EC</em>{50}$: Example 1 (Ideal Case)

• $K<em>d$ and $EC</em>{50}$ are similar or identical in the textbook ‘ideal’ case where drug effects are directly proportional to receptor occupancy. This occurs when:

  • There is a simple, direct relationship between receptor occupancy and the observed biological response.

  • The drug's maximal efficacy ($E_{max}$) is achieved only when virtually all receptors are occupied.

  • No 'spare receptors' exist, meaning every receptor must be bound to elicit a proportionate effect.

• In such cases, the concentration of drug required to occupy 50% of the receptors ($K<em>d$) is also the concentration required to elicit 50% of the maximal effect ($EC</em>{50}$).

$K<em>d$ versus $EC</em>{50}$: Example 2 (Spare Receptors)

• Spare receptors: These exist when the maximal response ($E_{max}$) can be achieved at a drug concentration that occupies only a fraction of the total available receptors. In other words, not all receptors need to be occupied to achieve the maximum possible pharmacologic effect. This means there are more receptors than are necessary to produce a full response.

• Physiological Significance: Spare receptors allow agonists to achieve maximal effects at lower concentrations than would otherwise be required, increasing the sensitivity of the system to the agonist and making responses more rapid and robust.

• Example: Insulin receptors have a significant “spare” receptor population ensuring strong glucose uptake at low hormone concentrations. This means that a relatively small percentage of insulin receptors need to be bound by insulin to elicit a maximal cellular response (e.g., maximal glucose transport into cells).

• In this context, $K<em>d$ (the concentration for 50% receptor occupancy) is typically higher than $EC</em>{50}$ (the concentration for 50% maximal effect) because a full effect is reached before all receptors are occupied.

Drugs: Efficacy versus Potency

• Efficacy (Maximal Efficacy): The greatest effect ($E_{max}$) a drug can produce. It reflects the inherent ability of a drug to produce a biological response once it has bound to its receptor. A drug with high efficacy can produce a stronger response than a drug with lower efficacy, regardless of the dose.

• Potency: Refers to the amount of drug needed to achieve a specified effect, usually 50% of its maximal effect ($EC_{50}$). A drug is considered more potent if a smaller dose or concentration is required to produce a given effect.

• The drug with the lower $EC<em>{50}$ or $K</em>d$ is deemed more potent, whereas the drug eliciting the greater effect (higher $E_{max}$) is considered more efficacious. It's crucial to distinguish these as a highly potent drug may have low efficacy, and vice-versa.

Quantal Dose–Response Curve

• The median effective dose ($ED<em>{50}$), median toxic dose ($TD</em>{50}$), and in animals median lethal dose ($LD_{50}$) are derived from experiments conducted to measure all-or-none responses in a population. These curves are used to characterize the variability of drug effects among individuals and to assess safety.

Definition:

• Quantal Dose–Response Curve: Measures binary (all-or-none) responses in a population. It shows the percentage of individuals who exhibit a specific effect (therapeutic, toxic, or lethal) at different doses of a drug.

• X-axis: Drug dose (or concentration), typically on a logarithmic scale.

• Y-axis: % of individuals showing a defined effect, plotted cumulatively.

Summary (Part I)

1. Pharmacodynamics (PD) vs. Pharmacokinetics (PK):

   • PD: What the drug does to the body (mechanisms, effects, actions).

   • PK: What the body does to the drug (ADME: Absorption, Distribution, Metabolism, Excretion).

2. Different Classes of Drugs:

   • Orthosteric vs. Allosteric: Distinctions based on where drugs bind to receptors.

   • Agonists vs. Antagonists: Distinctions based on whether drugs activate receptors or block agonist activity.

3. Receptor Occupancy Theory:

   • Binds to receptors to initiate effects: drugs must bind to specific molecular targets to exert their actions.

   • Binding characterized by affinity ($K_d$): the strength of drug-receptor interaction.

4. Dose–Response Curves:

   • Graded response: Measures % effect vs. drug concentration in a single system.

   • Key terms: $K<em>d$, $EC</em>{50}$, $E_{max}$, potency, efficacy, which quantify drug-receptor interactions and effects.

   • Quantal response: Population-based, showing $ED<em>{50}$, $LD</em>{50}$, and $TD_{50}$, used for assessing variability and safety.

Different Types of Agonists

• Agonist: Any molecule that binds to a receptor and produces a biological response. This implies both receptor affinity and intrinsic activity.

• Endogenous ligands: Include neurotransmitters, hormones, and growth factors that act as natural agonists within the body (e.g., acetylcholine for nicotinic receptors, dopamine for dopamine receptors, epinephrine/norepinephrine for adrenergic receptors).

• Types:

  • Full agonist: Binds to a receptor and produces the maximum possible biological response ($E_{max}$) achievable by that receptor system. It has intrinsic activity of 1.0. Even full agonists can differ in potency (affinity).

  • Partial agonist: Binds to a receptor and activates it, but is unable to produce the same maximal response as a full agonist, even when all receptors are occupied. It has intrinsic activity between 0 and 1.0. They typically have high affinity but lower efficacy.

  • Inverse agonist: Binds to the same site as an agonist (or allosterically) but produces an effect opposite to that of a full agonist (or a reduction below the basal constitutive activity). This occurs in systems where receptors have some constitutive (basal) activity even in the absence of a ligand. Inverse agonists stabilize the receptor in an inactive conformation. It has an intrinsic activity less than 0.

Different Types of Agonists - Summary Table

Full Agonists Differing in Potency

• Full agonists reach the same maximal effect ($E<em>{max}$) but may differ in potency (i.e., the concentration required to achieve 50% of $E</em>{max}$). A more potent drug will produce its maximal effect at a lower concentration.

• Example: If two full agonists are compared, the one with a lower $EC_{50}$ value is considered more potent. A leftward shift in the dose-response curve indicates higher potency, meaning less drug is needed for the same effect. For instance, nicotine shows a leftward shift in its dose-response curve compared to other agonists on the same receptor, indicating it is more potent.

Agonists Differing in Efficacy

• While full agonists all reach the same $E<em>{max}$ (defined as 1.0 for a given system), partial agonists will always have an $E</em>{max}$ less than 1.0 (submaximal effect), irrespective of the concentration used.

• Morphine: A potent full agonist at the $\mu$-opioid receptor, capable of reaching $E_{max}$ = 1.0 (maximal analgesia and other opioid effects).

• Buprenorphine: A partial agonist at the $\mu$-opioid receptor. It exhibits high potency (its dose-response curve may be left-shifted compared to full agonists due to high affinity) but displays partial efficacy, meaning its $E_{max}$ is inherently lower than that of morphine. This property can be useful in managing opioid addiction, as it can alleviate withdrawal symptoms without producing the full euphoric effects of a full agonist, and it has a ceiling effect for respiratory depression, improving safety.

Different Types of Antagonists

• An antagonist is a drug or molecule that binds to a receptor but does not interfere with its basal activity (has affinity but no efficacy), thereby blocking or reducing the effects of an agonist. Antagonists prevent agonists from binding and activating the receptor.

Antagonist Types:

1. Competitive Antagonists:

   • Binds reversibly to the same active (orthosteric) site as the agonist, competing for receptor binding.

   • Effects can be overcome by increasing agonist concentration: If the agonist concentration is sufficiently high, it can outcompete the antagonist for binding, eventually achieving the maximal effect ($E_{max}$).

   • Influence on the dose-response curve: It shifts the agonist dose-response curve to the right (increases $EC<em>{50}$ or reduces apparent potency) without changing the maximal effect ($E</em>{max}$). This is because higher agonist concentrations are needed to achieve the same effect in the presence of the competitive antagonist.

2. Non-competitive Antagonists:

   • Can bind to a different (allosteric) site on the receptor, leading to a conformational change that prevents agonist binding or activation, or it can bind irreversibly to the active site itself.

   • Effects on receptor availability/function: Reduces the number of functional receptors available for the agonist, regardless of how much agonist is present.

   • Influence on the dose-response curve: Typically decreases the maximal effect ($E<em>{max}$) of the agonist, making it impossible to achieve the original maximum response even with very high agonist concentrations. The $EC</em>{50}$ can remain unchanged (if the antagonist blocks the response without affecting agonist binding affinity) or slightly adjusted.

Competitive vs. Non-competitive Antagonists

• Competitive Antagonists: Shift the agonist curve to the right, indicating a decrease in apparent potency (higher $EC<em>{50}$) but no change in $E</em>{max}$ (maximal effect can still be reached).

• Non-competitive Antagonists: Shift the agonist curve downwards, indicating a decrease in $E<em>{max}$ (maximal effect cannot be reached), with potentially little to no change in $EC</em>{50}$. This is because the antagonist reduces the number of functional receptors or the efficiency of receptor signaling.

Graphical Presentation

• Graphs represent how competitive antagonism decreases potency (by increasing $EC<em>{50}$) and non-competitive antagonism decreases efficacy (by decreasing $E</em>{max}$), illustrating these characteristic shifts and their implications on drug response curves.

Types of Antagonists - Additional Categories

3. Physiological Antagonists:

   • Interact with different receptors or different physiological systems to produce opposing effects. They do not bind to the same receptor as the drug they antagonize.

   • Examples:

     • Antagonism of bronchoconstriction caused by histamine (acting on H1 receptors) through epinephrine's bronchodilator action (acting on ${\beta}_2$ adrenergic receptors). Both drugs act on different receptors to counteract each other's physiological effect.

     • Glucagon's antagonism of insulin’s hypoglycemic effects. Glucagon raises blood glucose (via glucagon receptors), while insulin lowers it (via insulin receptors).

4. Chemical Antagonists:

   • Interact directly with the drug being antagonized (not with a receptor) to remove or prevent it from binding to its target. This typically involves a chemical reaction.

   • Examples:

     • Dimercaprol, which chelates heavy metals like lead and some other toxic metals, forming a stable, non-toxic complex that can be excreted, preventing the metal from interacting with biological targets.

     • Protamine sulfate, which is positively charged, binds to negatively charged heparin (an anticoagulant) to form a stable, inactive complex, thereby reversing heparin's anticoagulant effects.

5. Functional Antagonists:

   • This category is sometimes used interchangeably with physiological antagonism, but it can also refer to the effects produced by partial agonists or inverse agonists that reduce a full agonist's effect while occupying the receptor, preventing a full response. They reduce the effective concentration of a full agonist.

   • Key differences from competitive antagonists include reducing the agonist’s efficacy while having its own intrinsic efficacy (for partial/inverse agonists).

Partial Agonist Activity Explained: Case of Varenicline

• Varenicline (Chantix): Functions as both a partial agonist and an antagonist at the nicotinic acetylcholine receptors (nAChRs), particularly the sub-type involved in nicotine addiction ($\alpha<em>4{\beta}</em>2$ nAChRs).

  • Partial Agonist Activity: Binds to nicotinic acetylcholine receptors, producing mild to moderate activation. This partial stimulation releases low levels of dopamine in the brain's reward pathway, helping to reduce nicotine withdrawal symptoms and cravings, as it satisfies some of the nicotine receptor activation without the full intensity of nicotine.

  • Antagonist Activity: If a person smokes while on Varenicline, Varenicline’s high affinity for the receptor outcompetes nicotine for the binding site. By occupying the receptor and providing only partial activation, it blocks nicotine from eliciting its full effect, thereby preventing the puissant dopamine release associated with the intense smoking reward effects, making smoking less pleasurable.

Tolerance vs. Tachyphylaxis

Drug effects may decline over time due to various adaptive changes in the body. Two key phenomena describing this decline are tolerance and tachyphylaxis.

Features:

Examples:

• Tolerance:

  • A gradual decrease in drug effect after chronic exposure, developing slowly due to receptor downregulation, increased metabolism, or compensatory adaptations (e.g., opioid analgesics: patients requiring progressively higher doses of morphine over time to achieve the same level of pain relief).

• Tachyphylaxis:

  • Rapid decrease in drug effect following short-term dosing, developing quickly due to receptor desensitization, mediator depletion (e.g., nasal decongestants like oxymetazoline: repeated, frequent use of nasal sprays can lead to rapidly diminishing effects due to depletion of norepinephrine stores and/or receptor desensitization, potentially causing rebound congestion).

Drug Selectivity

• Definition: How selectively a drug binds to and acts on its intended receptor or target, minimizing interactions with other targets.

• Key Concepts:

  • Selectivity refers to preferential activation or inhibition of the desired target over other potential off-targets. A drug is considered selective if it produces its therapeutic effects by acting on one primary receptor or enzyme, even if it can interact weakly with others.

  • High selectivity is characterized by low/no affinity for (or negligible effects on) other receptors or targets. This is highly desirable as it thus decreases potential off-target toxicity and adverse drug reactions.

  • The degree of selectivity can be quantified by calculating the ratio of $K<em>d$ or $EC</em>{50}$ values for different interactions (e.g., $[K<em>d \text{for Target B}] / [K</em>d \text{for Target A}]$). A larger ratio indicates greater selectivity for Target A.

  • Drug selectivity is crucial for successful drug development, leading to safer and more effective medications with fewer side effects.

Drug-Target Selectivity

Considerations:

• Between species:

  • In the context of antimicrobials or antiparasitics, prioritize unique targets in invading pathogens (bacteria, viruses, fungi, parasites) that are distinct from host targets. This ensures targeting is highly effective against the pathogen while not being harmful or minimally harmful to the host (e.g., antibiotics targeting bacterial cell wall synthesis).

• Within the body:

  • Focus on selectivity among different enzymes and receptors within the human body to minimize off-target effects. For example, targeting a pain-specific pathway without affecting cardiac function.

  • Emphasize distinction among receptor types and subtypes (e.g., targeting ${\beta}<em>1$ adrenergic receptors in the heart vs. ${\beta}</em>2$ adrenergic receptors in the lungs), and between isozymes (different forms of an enzyme) to achieve specific therapeutic effects with reduced side effects (e.g., selective COX-2 inhibitors for inflammation instead of non-selective COX inhibitors).

Improving Drug Selectivity

• Improving drug selectivity is an essential step in drug discovery, particularly during the hit-to-lead optimization phase, where initial drug candidates are refined. This may involve:

  • Structure-Activity Relationship (SAR) studies: Modifying the chemical structure of a compound to enhance its affinity for the desired target while reducing its affinity for off-targets.

  • High-throughput screening: Testing compounds against a panel of targets to identify selective agents.

  • Kinase selectivity profiling: For enzyme inhibitors, testing against a broad panel of kinases to find inhibitors highly specific for the desired kinase.

  • Genetic knock-out studies: Testing drug activity in target cells versus cells with the target gene knocked out, to confirm on-target effects.

Therapeutic Index (TI)

Definition:

• A measure of a drug’s safety margin, defined as the ratio between doses that cause toxic effects and those that produce therapeutic effects. It is derived from quantal dose-response curves.

• Formula:

  $\text{TI} = \frac{TD<em>{50}}{ED</em>{50}}$

  • Where:

    • $\textbf{ED}_{50}$: Median Effective Dose; the dose that produces a therapeutic effect in 50% of the population.

    • $\textbf{TD}<em>{50} \text{ / } \textbf{LD}</em>{50}$: Median Toxic Dose (or Median Lethal Dose); the dose that produces a toxic effect in 50% of the population ($TD<em>{50}$) or is lethal in 50% of animals ($LD</em>{50})$.

Interpretation:

1. A high TI indicates a safer drug (large margin between effective and toxic doses). This means there is a wide range of doses that will be effective without causing significant toxicity.

2. A low TI indicates a narrow safety margin, requiring careful monitoring of drug levels and patient response to avoid toxicity (e.g., drugs like warfarin or digoxin).

Examples:

• Wide TI: Penicillin (very high doses are required to produce toxicity, while effective doses are relatively low), Benzodiazepines (generally safe at therapeutic doses).

• Narrow TI: Digoxin (used for heart conditions, toxic dose is not much higher than therapeutic dose), Warfarin (an anticoagulant, requires close monitoring due to narrow window between efficacy and bleeding risk), Lithium (mood stabilizer), narrow range between therapeutic and toxic levels, requiring frequent blood level checks.

Assessing Therapeutic Index

• Recommendations state to maximize the TI; an approximate value greater than 10 is considered high, implying a relatively safe drug. However, for some critical drugs, a lower TI may be accepted due to the severity of the condition being treated if no safer alternatives exist.

Comparing Therapies

Quantal Dose-Response Curves

• Quantal dose-response curves not only provide $ED<em>{50}$ and $TD</em>{50}$, but their slopes can also provide insights into the variability of individual responses within a population. A steeper slope indicates less individual variability.

Implications of Slope:

• Low slope: Signifies greater variability in patient response to a drug and reflects diverse pharmacokinetics (e.g., differences in ADME) and/or pharmacodynamics (e.g., differences in receptor expression or signal transduction efficiency) among individuals. This means patients may respond differently to the same dose.

• High slope: Indicates more uniform drug sensitivity among the population. A small increase in dose can lead to a large increase in the percentage of responders (or affected individuals).

Advantages/Disadvantages of a High-Slope Quantal Curve:

• Advantages:

  • Predictable dosing: For a given dose, the percentage of responders is highly consistent across trials (assuming a homogenous population).

  • Beneficial for critical or fast-acting therapies (e.g., anesthetics, where a rapid, uniform response is desired without much individual variation).

• Disadvantages:

  • Narrow safety margins if toxicity also has a steep slope: A small dose increment beyond the therapeutic range can quickly lead to a large proportion of the population experiencing toxic effects, making overdosing a significant risk.

  • Low tolerance for dosing errors or patient variability: Requires precise dosing and careful consideration of individual patient factors, as even minor deviations can have significant clinical consequences.

Reviewing Learning Objectives

By the end of this lecture, students should be able to:

1. Define pharmacodynamics (PD) and distinguish it from pharmacokinetics (PK).

2. Describe Receptor Occupancy Theory – how receptor binding (occupancy) translates into pharmacologic effect.

3. Evaluate dose-response curves to determine key drug properties (graded vs. quantal, $K<em>d$, $EC</em>{50}$, $E<em>{max}$, potency, efficacy, $ED</em>{50}$, $LD_{50}$).

4. Differentiate classes of drugs based on their mechanisms of action (orthosteric vs. allosteric, agonist vs. antagonist, reversible vs. irreversible) with representative examples.

5. Explain tolerance and tachyphylaxis, and why drug effects may decline over time.

6. Define therapeutic index (TI) and discuss its role in drug safety and selectivity.

7. Apply these concepts to real-life drug examples.